The design of antigen delivery systems, particularly for mucosal surfaces, has been a focus of interest in recent years. In this chapter, we describe the preparation of chitosan-based particles as promising antigen delivery systems for mucosal surfaces already tested by our group with hepatitis B surface antigen. The final proof of the concept is always carried out with immunization studies performed in an appropriate animal model. However, before these important studies, it is advisable that the delivery system should be submitted to a variety of in vitro tests. Among several tests, the characterization of the particles (size, morphology, and zeta potential), the studies of antigen adsorption onto particles, the evaluation of toxicity of the particles, and the studies of particle uptake into lymphoid organs are the most important and will be described in this chapter.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/B978-0-12-391858-1.00007-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recent advances in bacterial outer membrane vesicles: Effects on the immune system, mechanisms and their usage for tumor treatment.
J Pharm Anal
December 2024
Center for AIE Research, Shenzhen Key Laboratory of Polymer Science and Technology, Guangdong Research Center for Interfacial Engineering of Functional Materials, College of Materials Science and Engineering, Shenzhen University, Shenzhen, Guangdong, 518060, China.
Tumor treatment remains a significant medical challenge, with many traditional therapies causing notable side effects. Recent research has led to the development of immunotherapy, which offers numerous advantages. Bacteria inherently possess motility, allowing them to preferentially colonize tumors and modulate the tumor immune microenvironment, thus influencing the efficacy of immunotherapy.
View Article and Find Full Text PDFVirus-like particle: a nano-platform that delivers cancer antigens to elicit an anti-tumor immune response.
Front Immunol
January 2025
School of Medicine, Wuhan University of Science and Technology, Wuhan, Hubei, China.
Virus-like particles (VLPs), as a unique form of nanocarrier, predominantly encompass hollow protein shells that exhibit analogous morphology and structure to naturally occurring viruses, yet devoid of genetic material. VLPs are considered safe, easily modifiable, and stable, making them suitable for preparation in various expression systems. They serve as precise biological instruments with broad applications in the field of medical biology.
View Article and Find Full Text PDFA novel oncolytic Vaccinia virus armed with IL-12 augments antitumor immune responses leading to durable regression in murine models of lung cancer.
Front Immunol
January 2025
Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China.
Oncolytic vaccinia viruses (VVs) are potent stimulators of the immune system and induce immune-mediated tumor clearance and long-term surveillance against tumor recurrence. As such they are ideal treatment modalities for solid tumors including lung cancer. Here, we investigated the use of VVL-m12, a next-generation, genetically modified, interleukin-12 (IL-12)-armed VV, as a new therapeutic strategy to treat murine models of lung cancer and as a mechanism of increasing lung cancer sensitivity to antibody against programmed cell death protein 1 (α-PD1) therapy.
View Article and Find Full Text PDFA bioluminescent reporter bioassay for in-process assessment of chimeric antigen receptor lentiviral vector potency.
Antib Ther
January 2025
Research and Development, Promega Corp., Madison, WI 53711, United States.
Background: Chimeric antigen receptor (CAR)-T-cell therapy is a breakthrough in the field of cancer immunotherapy, wherein T cells are genetically modified to recognize and attack cancer cells. Delivery of the CAR gene is a critical step in this therapy and is usually achieved by transducing patient T cells with a lentiviral vector (LV). Because the LV is an essential component of CAR-T manufacturing, there is a need for simple bioassays that reflect the mechanism of action (MOA) of the LV and can measure LV potency with accuracy and specificity.
View Article and Find Full Text PDFNanotechnology-based approaches for targeted drug delivery for the treatment of respiratory tract infections.
J Biol Methods
October 2024
Department of Biochemistry, Sismanogleio Hospital, Athens 15126, Greece.
Background: Nanotechnology has emerged as a promising field for the diagnosis, monitoring, and treatment of respiratory tract infections (RTIs). By leveraging the unique properties of nanoscale delivery systems, nanotechnology can significantly enhance the selectivity and efficacy of antimicrobials, thereby reducing off-target effects.
Objective: This review explores the development and application of targeted nanosystems in combating viral, bacterial, and fungal RTIs.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!